Chemokines in the pathogenesis of vascular disease.
暂无分享,去创建一个
[1] Steffen Jung,et al. The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. , 2001, The Journal of clinical investigation.
[2] F. Luscinskas,et al. Fractalkine Preferentially Mediates Arrest and Migration of CD16+ Monocytes , 2003, The Journal of experimental medicine.
[3] Melinda Fitzgerald,et al. Immunol. Cell Biol. , 1995 .
[4] T. Kita,et al. Molecular Cloning of a Novel Scavenger Receptor for Oxidized Low Density Lipoprotein, SR-PSOX, on Macrophages* , 2000, The Journal of Biological Chemistry.
[5] N. Maeda,et al. CCR5 deficiency is not protective in the early stages of atherogenesis in apoE knockout mice. , 2003, Atherosclerosis.
[6] R. Doms,et al. Influence of the CCR2-V64I Polymorphism on Human Immunodeficiency Virus Type 1 Coreceptor Activity and on Chemokine Receptor Function of CCR2b, CCR3, CCR5, and CXCR4 , 1998, Journal of Virology.
[7] B. Rollins,et al. MCP‐1‐dependent signaling in CCR2−/− aortic smooth muscle cells , 2004, Journal of leukocyte biology.
[8] I. Charo,et al. Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. , 2003, The Journal of clinical investigation.
[9] S. Gordon,et al. Linked Chromosome 16q13 Chemokines, Macrophage-Derived Chemokine, Fractalkine, and Thymus- and Activation-Regulated Chemokine, Are Expressed in Human Atherosclerotic Lesions , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[10] Y. Kawakami,et al. The role of the C-C chemokine receptor 2 gene polymorphism V64I (CCR2-64I) in sarcoidosis in a Japanese population. , 1999, American journal of respiratory and critical care medicine.
[11] E. Prossnitz,et al. The role of the third intracellular loop of the neutrophil N-formyl peptide receptor in G protein coupling. , 1993, The Biochemical journal.
[12] S M Schwartz,et al. Developmental mechanisms underlying pathology of arteries. , 1990, Physiological reviews.
[13] M. Reidy,et al. Factors controlling the development of arterial lesions after injury. , 1992, Circulation.
[14] B. Rollins,et al. Tissue Factor Is Induced by Monocyte Chemoattractant Protein-1 in Human Aortic Smooth Muscle and THP-1 Cells* , 1997, The Journal of Biological Chemistry.
[15] B. Rollins,et al. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[16] B. Rollins,et al. Abnormalities in Monocyte Recruitment and Cytokine Expression in Monocyte Chemoattractant Protein 1–deficient Mice , 1998, The Journal of experimental medicine.
[17] O. Quehenberger,et al. Expression of the monocyte chemoattractant protein-1 receptor CCR2 is increased in hypercholesterolemia. Differential effects of plasma lipoproteins on monocyte function. , 1999, Journal of lipid research.
[18] P. Kubes,et al. Human fractalkine mediates leukocyte adhesion but not capture under physiological shear conditions; a mechanism for selective monocyte recruitment , 2003, European journal of immunology.
[19] N. Maeda,et al. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. , 1999, Atherosclerosis.
[20] B. Rollins,et al. JE mRNA accumulates rapidly in aortic injury and in platelet-derived growth factor-stimulated vascular smooth muscle cells. , 1992, Circulation research.
[21] U. Ikeda,et al. Monocyte chemoattractant protein 1 inhibits growth of rat vascular smooth muscle cells. , 1995, The American journal of physiology.
[22] J. Bernhagen,et al. Stabilization of Atherosclerotic Plaques by Blockade of Macrophage Migration Inhibitory Factor After Vascular Injury in Apolipoprotein E–Deficient Mice , 2004, Circulation.
[23] W. Kuo,et al. A physical map of chromosome 20 established using fluorescence in situ hybridization and digital image analysis. , 1995, Genomics.
[24] Gerrity Rg,et al. Ultrastructural identification of monocyte-derived foam cells in fatty streak lesions. , 1980 .
[25] Ose,et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events* , 2002 .
[26] I. Charo,et al. Molecular Uncoupling of Fractalkine-mediated Cell Adhesion and Signal Transduction , 1999, The Journal of Biological Chemistry.
[27] P. Dempsey,et al. A Disintegrin and Metalloproteinase 10-Mediated Cleavage and Shedding Regulates the Cell Surface Expression of CXC Chemokine Ligand 16 , 2004, The Journal of Immunology.
[28] U. Ikeda,et al. Expression of intercellular adhesion molecule-1 on rat vascular smooth muscle cells by pro-inflammatory cytokines. , 1993, Atherosclerosis.
[29] T. Katagiri,et al. Monocyte chemotactic protein 1 amplifies serotonin-induced vascular smooth muscle cell proliferation. , 2002, Journal of vascular research.
[30] P. Libby,et al. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. , 2004, The American journal of medicine.
[31] C. Weber,et al. Chemokine receptor (CCR2) genotype is associated with myocardial infarction and heart failure in patients under 65 years of age , 2003, Journal of Molecular Medicine.
[32] R. D'Agostino,et al. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. , 2003, The Journal of clinical investigation.
[33] A. J. Valente,et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[34] G. McFadden,et al. The viral anti-inflammatory chemokine-binding protein M-T7 reduces intimal hyperplasia after vascular injury. , 2000, The Journal of clinical investigation.
[35] P. Libby. Inflammation in atherosclerosis , 2002, Nature.
[36] Steffen Jung,et al. Blood monocytes consist of two principal subsets with distinct migratory properties. , 2003, Immunity.
[37] U. V. von Andrian,et al. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. , 2004, Annual review of immunology.
[38] D. Dichek,et al. Adhesion of monocytes to vascular cell adhesion molecule-1-transduced human endothelial cells: implications for atherogenesis. , 1998, Circulation research.
[39] A. Quyyumi,et al. Association Between Polymorphism in the Chemokine Receptor CX3CR1 and Coronary Vascular Endothelial Dysfunction and Atherosclerosis , 2001, Circulation research.
[40] Wei Wang,et al. A new class of membrane-bound chemokine with a CX3C motif , 1997, Nature.
[41] J J Goedert,et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. , 1997, Science.
[42] F. Welt,et al. Targeting CCR2 or CD18 Inhibits Experimental In-Stent Restenosis in Primates: Inhibitory Potential Depends on Type of Injury and Leukocytes Targeted , 2002, Circulation research.
[43] S. Coughlin,et al. Monocyte chemoattractant protein-1 in human atheromatous plaques. , 1991, The Journal of clinical investigation.
[44] D. Steinberg. Oxidative Modification of LDL and Atherogenesis , 1998 .
[45] Sharon Engel,et al. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo , 2000, Nature Immunology.
[46] I. Charo,et al. Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis , 1998, Nature.
[47] Osamu Yoshie,et al. Cutting Edge: Profile of Chemokine Receptor Expression on Human Plasma Cells Accounts for Their Efficient Recruitment to Target Tissues 1 , 2003, The Journal of Immunology.
[48] F. Mach,et al. Antagonism of RANTES Receptors Reduces Atherosclerotic Plaque Formation in Mice , 2004, Circulation research.
[49] J. Badimón,et al. CCR2 Deficiency Decreases Intimal Hyperplasia After Arterial Injury , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[50] R. Gerrity,et al. Ultrastructural identification of monocyte-derived foam cells in fatty streak lesions. , 1980, Artery.
[51] E. Boerwinkle,et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. , 2003, Circulation.
[52] I. Charo,et al. Tumor Necrosis Factor- (cid:1) -converting Enzyme Mediates the Inducible Cleavage of Fractalkine* , 2022 .
[53] M. Voskuil,et al. Effects of local MCP-1 protein therapy on the development of the collateral circulation and atherosclerosis in Watanabe hyperlipidemic rabbits. , 2003, Cardiovascular research.
[54] W. Schaper,et al. Collateral Artery Growth (Arteriogenesis) After Experimental Arterial Occlusion Is Impaired in Mice Lacking CC-Chemokine Receptor-2 , 2004, Circulation research.
[55] Robert V Farese,et al. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. , 1997, The Journal of clinical investigation.
[56] D. Soler,et al. Expression Cloning of the STRL33/BONZO/TYMSTR Ligand Reveals Elements of CC, CXC, and CX3C Chemokines , 2001, The Journal of Immunology.
[57] W. Kübler,et al. Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-kappaB and activator protein-1. , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[58] T. Kurihara,et al. Cloning and Functional Expression of mCCR2, a Murine Receptor for the C-C Chemokines JE and FIC (*) , 1996, The Journal of Biological Chemistry.
[59] E. Antman,et al. Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndromes , 2003, Circulation.
[60] B. Rollins,et al. Transgenic monocyte chemoattractant protein-1 (MCP-1) in pancreatic islets produces monocyte-rich insulitis without diabetes: abrogation by a second transgene expressing systemic MCP-1. , 1997, Journal of immunology.
[61] J. Gutiérrez-Ramos,et al. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation , 1997, Nature.
[62] Marc W. Kirschner,et al. A PtdInsP3- and Rho GTPase-mediated positive feedback loop regulates neutrophil polarity , 2002, Nature Cell Biology.
[63] A. Takeshita,et al. Importance of Monocyte Chemoattractant Protein-1 Pathway in Neointimal Hyperplasia After Periarterial Injury in Mice and Monkeys , 2002, Circulation research.
[64] A. J. Valente,et al. Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[65] K. Ley,et al. Deposition of Platelet RANTES Triggering Monocyte Recruitment Requires P-Selectin and Is Involved in Neointima Formation After Arterial Injury , 2002, Circulation.
[66] T. Kita,et al. Cell surface‐anchored SR‐PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6‐expressing cells , 2004, Journal of leukocyte biology.
[67] R. Ross,et al. Growth Regulatory Mechanisms and Formation of the Lesions of Atherosclerosis a , 1994, Annals of the New York Academy of Sciences.
[68] Armin Helisch,et al. Arteriogenesis The Development and Growth of Collateral Arteries , 2003, Microcirculation.
[69] Jingsong Xu,et al. Divergent Signals and Cytoskeletal Assemblies Regulate Self-Organizing Polarity in Neutrophils , 2003, Cell.
[70] A. Alcamí,et al. Inhibition of intimal hyperplasia in transgenic mice conditionally expressing the chemokine-binding protein M3. , 2004, The American journal of pathology.
[71] M. Voskuil,et al. Local Monocyte Chemoattractant Protein-1 Therapy Increases Collateral Artery Formation in Apolipoprotein E–Deficient Mice but Induces Systemic Monocytic CD11b Expression, Neointimal Formation, and Plaque Progression , 2003, Circulation research.
[72] A. Matsumori,et al. Anti-monocyte chemoattractant protein-1/monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. , 1999, Circulation research.
[73] B. Brenner,et al. Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. , 2002, Journal of the American Society of Nephrology : JASN.
[74] Weixin Zhao,et al. Human Vascular Smooth Muscle Cells Possess Functional CCR5* , 2000, The Journal of Biological Chemistry.
[75] D. Salant,et al. Targeted deletion of CX3CR1 reveals a role for fractalkine in cardiac allograft rejection , 2001 .
[76] R. Ross,et al. Studies of Hypercholesterolemia in the Nonhuman Primate: I. Changes that Lead to Fatty Streak Formation , 1984, Arteriosclerosis.
[77] B. Rollins,et al. MCP-1 deficiency is associated with reduced intimal hyperplasia after arterial injury. , 2003, Biochemical and biophysical research communications.
[78] A. Luster,et al. Murine Monocyte Chemoattractant Protein (MCP)-5: A Novel CC Chemokine That Is a Structural and Functional Homologue of Human MCP-1 , 1997, The Journal of experimental medicine.
[79] Christine M. Miller,et al. CCL11 (Eotaxin) Induces CCR3-Dependent Smooth Muscle Cell Migration , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[80] Y. Minami,et al. Fractalkine, a CX3C‐chemokine, functions predominantly as an adhesion molecule in monocytic cell line THP‐1 , 2001, Immunology and cell biology.
[81] P. Debré,et al. Decreased Atherosclerotic Lesion Formation in CX3CR1/Apolipoprotein E Double Knockout Mice , 2003, Circulation.
[82] D. Salant,et al. Targeted deletion of CX(3)CR1 reveals a role for fractalkine in cardiac allograft rejection. , 2001, The Journal of clinical investigation.
[83] J. Fallon,et al. Chemokine receptor-8 (CCR8) mediates human vascular smooth muscle cell chemotaxis and metalloproteinase-2 secretion. , 2004, Blood.
[84] M. Loda,et al. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1 , 2000, Nature.
[85] B. Rollins,et al. Chemokines and disease , 2001, Nature Immunology.
[86] J. Badimón,et al. Mouse model of femoral artery denudation injury associated with the rapid accumulation of adhesion molecules on the luminal surface and recruitment of neutrophils. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[87] R. Terkeltaub,et al. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. , 1998, The Journal of clinical investigation.
[88] G. Mancia,et al. Treatment of Hypertension and Ischemic Heart Disease , 1989, Journal of cardiovascular pharmacology.
[89] P. Norman,et al. Monocyte chemoattractant protein‐1 gene expression in injured pig artery coincides with early appearance of infiltrating monocyte/macrophages , 1996, Journal of cellular biochemistry.
[90] Andrew C. Li,et al. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma. , 2000, The Journal of clinical investigation.
[91] Antonio Colombo,et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. , 2003, Circulation.
[92] U. Hedin,et al. CXCL16/SR-PSOX Is an Interferon-&ggr;–Regulated Chemokine and Scavenger Receptor Expressed in Atherosclerotic Lesions , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[93] P. Libby,et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. , 1998, Molecular cell.
[94] F. Luscinskas,et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions , 1999, Nature.
[95] D. Steinberg,et al. Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. , 1997, Circulation.
[96] D. Rader,et al. Val64Ile Polymorphism in the C-C Chemokine Receptor 2 Is Associated With Reduced Coronary Artery Calcification , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[97] D. Patel,et al. Fractalkine and CX3CR1 Mediate a Novel Mechanism of Leukocyte Capture, Firm Adhesion, and Activation under Physiologic Flow , 1998, The Journal of experimental medicine.
[98] A. Schober,et al. Crucial Role of Stromal Cell–Derived Factor-1&agr; in Neointima Formation After Vascular Injury in Apolipoprotein E–Deficient Mice , 2003, Circulation.
[99] B. Rollins,et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. , 1999, The Journal of clinical investigation.
[100] M. Reidy,et al. Regulation of Smooth Muscle Cell Growth in Injured Artery , 1989, Journal of cardiovascular pharmacology.